Hey I am on Medial • 2d
Let's be real - Molbio's revenue chart is essentially a COVID bubble, not a sustainable growth story. Yes, they went from 51Cr to 1,272Cr, but then immediately fell back to 332Cr post-pandemic. That's a 74% revenue DROP in just two years. Their projected 1,200Cr for FY25 sounds suspiciously convenient for IPO timing - I'd be extremely skeptical of those projections. The valuation of 22,000-24,000Cr is about 20x their projected revenue, which is absurdly high for a biotech hardware company with this much volatility. For comparison, traditional medtech companies trade at 3-5x revenue. This has all the hallmarks of trying to cash in before the growth story falls apart. I'm staying far away from this one.
Download the medial app to read full posts, comements and news.